# A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid

> **NCT04499235** · PHASE2 · TERMINATED · sponsor: **Alkahest, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Pemphigoid, Bullous

## Interventions

- **DRUG:** Mometasone furoate
- **DRUG:** AKST4290
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04499235
- **Lead sponsor:** Alkahest, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-30
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-04-14
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** The study was prematurely terminated by the Sponsor due to operational challenges stemming from the coronavirus disease 2019 (COVID-19) pandemic, treatment limitations, rarity of the disease, and drug supply considerations.
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04499235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04499235, "A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04499235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*